KRAS P.G12C
Clinical trials for KRAS P.G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS P.G12C trials appear
Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
Disease control Recruiting nowThis phase 2 trial is testing a daily pill called sotorasib (AMG510) in people with stage III lung cancer that has a specific genetic change (KRAS G12C) and cannot be treated with standard chemotherapy plus radiation. The study will enroll about 19 participants to see if the drug…
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New pill targets Hard-to-Treat cancer mutation
Disease control Recruiting nowThis study tests a new oral drug called D3S-001, alone or with other cancer drugs, in people with advanced solid tumors that have a specific KRAS G12C mutation. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 442 participants will …
Matched conditions: KRAS P.G12C
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New targeted pill shows promise for Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC